PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 212 (xsd:integer)
nif:isString
  • In vivo, sorafenib has been administered in phase II clinical trials to patients with urothelial carcinoma (UC) who had been treated with one prior chemotherapy regimen [3] and to patients with metastatic UC [4].
rdf:type